AstraZeneca shares in tentative rebound

AstraZeneca, the pharmaceutical group, reported that its COVID-19 vaccine has been approved for emergency supply in the U.K. and vaccinations may begin early in the New Year.

Charts (6)

AstraZeneca, the pharmaceutical group, reported that its COVID-19 vaccine has been approved for emergency supply in the U.K. and vaccinations may begin early in the New Year.

From a chartist’s point of view, the stock price is holding above a key support at 7121p and is rebounding from the lower end of a bearish channel. The daily RSI has landed on a key support around 30% and is reversing up. A technical rebound could be on the cards. A break above 7880p (upper channel boundary) would validate a bullish signal with 8140p and 8848p as targets. Alternatively, a break below 7121p would negate the bullish view and would call for a slump towards 6315p and 5871p (congestion zone).

Source: GAIN Capital, TradingView


More from Equities

Disclaimer

This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

StoneX Financial Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.